ROCKVILLE, Md., April 21 /PRNewswire/ -- Theranostics Health announced
that it has received an exclusive license from the National Institutes of
Health (NIH) to commercialize microdissection including Laser Capture
Microdissection (LCM) combined with protein analysis for cancer diagnostics
and companion diagnostics. Under the terms of the agreement, Theranostics
Health will pay NIH the customary license issue royalties, minimum annual
royalties, benchmark and earned royalties upon successful commercialization
of the technology.

Theranostics was founded on the vision of shaping a new paradigm in
disease management with two primary and complementary goals; arming
physicians with accurate diagnostic tests so that they can tailor treatment
based on the individual patient's aberrant signaling profile and enabling
drug developers to better stratify clinical cohorts in clinical trials to
efficiently develop safer and more effective drugs.

Dr. Lance Liotta, co-inventor of the technology, co-founder and Chief
Medical Officer of the Company said, "Existing methods of genomic and
proteomic tissue profiling analysis that do not rely on LCM have been shown
to produce inaccurate and possibly misleading results, arising from
heterogeneity of tissues and variation in cellular compositions between
samples and within different regions of a tissue sample. This licensed
technology allows us to precisely collect and analyze the specific cells of
interest from patient samples." "But this is only the first step,"
according to Dr. Emanuel F. Petricoin, co-inventor of the technology,
co-founder and Chief Scientific Officer of the Company, "our unique
signaling pathway profiling platform allows the activity of theranostic
biomarkers of interest to be quantitatively measured from microdissected
patient samples. With this technology and our experience and expertise in
disease signaling pathways, we are discovering new ways of more effectively
treating patients with existing drugs and treating patients who are
resistant to their current therapies."

"This exclusive license allows Theranostics Health to commercially
develop companion diagnostics for treatment decision and monitoring,
providing direct benefit to patients as well as building significant value
for our shareholders," added the Company's President and CEO, Dr. Danong
Chen.

About Theranostics Health

Theranostics Health is a privately held company founded in 2006. Its
core technology is the breakthrough Reverse Phase Protein Microarray (RPMA)
combined with Laser Capture Microdissection (LCM). The technology measures
the activity of a large number of biomarkers, enabling pharmaceutical
companies to accurately profile their drug candidates to facilitate
efficient and effective drug development. More importantly, it enables
physicians to tailor optimized therapies to their patients based on the
biomarker profile of each individual patient, providing safer and more
effective therapies. The technology, invented by the company's co-founders
Drs. Emanuel Petricoin and Lance Liotta, was first published by them in
2001, has been featured in over 50 peer-reviewed publications and 20
scientific presentations within the past 2 years, and was successfully used
in NCI-sponsored clinical trials. Currently, Theranostics Health is working
with 5 of the top 10 global pharmaceutical companies in their drug R&D
efforts. The company closed its seed financing of $5 million in 2007 and
generated revenue in its first year of operations. For more information
please email info@theranosticshealth.com or visit
http://www.theranosticshealth.com.

(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... The next ... now being accepted. , Students who successfully complete the seven-week long Patient Care ... Nurse Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* ...

(Date:8/16/2017)... ... 2017 , ... Greenfield Advisors is honored to be named to Inc. Magazine’s ... in a row. The Inc. 5000 list honors private businesses across the country that ... list once is a great accomplishment, but for us to be included again goes ...

(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...

(Date:8/16/2017)... New York (PRWEB) , ... August 16, 2017 , ... ... could minimize its appearance with diet and exercise. In fact, cellulite can't always be ... a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus ...

(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...

(Date:8/4/2017)... , Aug. 3, 2017 Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131. This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...